Fiocruz, as the foundation is known, will spend US$142 million to buy the vaccines and to build a plant to carry out secondary production for GSK. The vaccines will be made in Belgium, then packaged, labeled and distributed in Brazil. The plant, which is expected to begin operations in the second half of 2004, represents a big step forward in the country's pharmaceutical sector, says Russell Greig, president for pharmaceuticals international at GSK.
"As expertise grows, [Brazil] will go up the feeding chain and start producing vaccines," says Greig. The company's vaccine sales grew an estimated 12% in developing markets from 2000 to 2002, which Greig attributes to governments recognizing the need to improve healthcare standards. Such plants also represent significant foreign investment.
But GSK isn't ready to make a deal with the rest of the region out of fear that its vaccine formula could slip out. "Building trust is an important element to these deals," says Greig.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Trade Talk|
|Article Type:||Brief Article|
|Date:||Jan 1, 2004|
|Previous Article:||Pink slipped.|
|Next Article:||Chat line.|